AgomAb Therapeutics NV (AGMB) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Valneva is the larger company by market cap ($539.5 million vs $454.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | VALN |
|---|---|---|
| Share price | $9.22 | $5.69 |
| Market cap | $454.07M | $539.55M |
| 1-day change | +4.77% | -3.07% |
| YTD return | — | -35.49% |
| 1-year return | — | -48.41% |
| 5-year return | — | -79.07% |
| Forward P/E | — | 4.78 |
| EPS (TTM) | $-2.16 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $12.18 |
| 52-week low | $7.97 | $4.75 |
| Distance from 52-week high | -48.26% | -53.28% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +308.57% | +115.29% |
| Average volume | 139.21K | 78.17K |
| Shares outstanding | 49.25M | 94.82M |
| Employees | 62 | 620 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees
AGMB vs VALN FAQ
Which is bigger, AgomAb Therapeutics NV or Valneva?
Valneva (VALN) is larger, with a market capitalization of $539.55M compared with $454.07M for AgomAb Therapeutics NV (AGMB).
Are AgomAb Therapeutics NV and Valneva in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.